Roche Forges Ahead With Taspoglutide Despite Cancer Signal With Competitor GLP-1

Roche expects Phase III data on the type 2 diabetes drug to be available by the end of the year and maintains that any carcinogenicity issue is rodent-specific.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet